Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Papaverine Hydrochloride

    Client Email Product

    Papaverine Hydrochloride

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    24
    US DMFs Filed

    US DMFs Filed

    7
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    1
    Other Certificates

    Other Certificates

    2
    Other Suppliers

    Other Suppliers

    18
    API REF. PRICE (USD / KG)
    208

    API Market Place

    16
    INTERMEDIATES
    3
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    8
    Canada

    Canada

    1
    Australia

    Australia

    0

    South Africa

    South Africa

    1
    Uploaded Dossiers

    Uploaded Dossiers

    5
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    5
    EXCIPIENTS
    1
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    18
    REF STANDARD

    EDQM

    0

    USP

    1

    JP

    0

    Other Listed Suppliers

    9
    SERVICES

    0

    Full View ScreenFull Screen View
    Enforcement Report - Week of January 18, 2023
    Enforcement Report - Week of January 18, 2023

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-18-2023-33998.pdf

    FDA
    18 Jan 2023
    Share Share
    Enforcement Report - Week Of June 01, 2022
    Enforcement Report - Week Of June 01, 2022

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-01-2022-1654158193.pdf

    FDA
    01 Jun 2022
    Share Share
    Enforcement Report - Week of April 13, 2022
    Enforcement Report - Week of April 13, 2022

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-13-2022-1649826529.pdf

    FDA
    13 Apr 2022
    Share Share
    Enforcement Report - Week of March 23, 2022
    Enforcement Report - Week of March 23, 2022

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-23-2022-1648013269.pdf

    FDA
    23 Mar 2022
    Share Share
    Enforcement Report - Week of November 17, 2021
    Enforcement Report - Week of November 17, 2021

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-17-2021-1637135168.pdf

    FDA
    17 Nov 2021
    Share Share
    Enforcement Report - Week of March 11, 2020
    Enforcement Report - Week of March 11, 2020

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-11-2020-1583989701.pdf

    FDA
    12 Mar 2020
    Share Share
    Enforcement Report - Week of January 22, 2020
    Enforcement Report - Week of January 22, 2020

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-22-2020-1579699881.pdf

    FDA
    22 Jan 2020
    Share Share
    Enforcement Report - Week of July 17, 2019
    Enforcement Report - Week of July 17, 2019

    FDA
    17 Jul 2019
    Share Share
    Enforcement Report - Week of June 19, 2019
    Enforcement Report - Week of June 19, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-19-2019-1560925761.pdf

    FDA
    19 Jun 2019
    Share Share
    Enforcement Report - Week of May 8, 2019
    Enforcement Report - Week of May 8, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-8-2019-1557294096.pdf

    FDA
    08 May 2019
    Share Share
    Enforcement Report - Week of April 17, 2019
    Enforcement Report - Week of April 17, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-17-2019-1555476880.pdf

    FDA
    17 Apr 2019
    Share Share
    Enforcement Report - Week of November 7, 2018
    Enforcement Report - Week of November 7, 2018

    https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-November-7-2018-1541578996.pdf

    FDA
    07 Nov 2018
    Share Share
    Enforcement Report - Week of August 22, 2018
    Enforcement Report - Week of August 22, 2018

    https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-August-22-2018-1534903909.pdf

    FDA
    22 Aug 2018
    Share Share
    Enforcement Report - Week of January 17, 2018
    Enforcement Report - Week of January 17, 2018

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-17-2018-1516166737.pdf

    FDA
    17 Jan 2018
    Share Share
    Enforcement Report - Week of May 24, 2017
    Enforcement Report - Week of May 24, 2017

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-24-2017-1495779323.pdf

    FDA
    24 May 2017
    Share Share
    US FDA Enforcement report- 13/Apr/2016
    US FDA Enforcement report- 13/Apr/2016

    https://www.pharmacompass.com/pdf/news/us-fda-enforcement-report-13apr2016-1460549225.pdf

    FDA
    12 Apr 2016
    Share Share
    Broken Market for Old Drugs Means Price Spikes Are Here to Stay
    Broken Market for Old Drugs Means Price Spikes Are Here to Stay

    http://www.bloomberg.com/news/articles/2015-11-18/the-law-of-pharma-pricing-physics-what-goes-up-often-stays-up

    Cynthia Koons BLOOMBERG
    18 Nov 2015
    Share Share
    Vann Healthcare Services Inc, Ongoing Class II recall of Tri-mix #4 (Papaverine 30 mg, Phentolamine 1 mg, Prostaglandin-1 10 mcg/mL), packaged in 10 mL sterile glass vials, Rx, Vann Healthcare Pharmacy, 1220 N Race Street, Glasgow, KY 42141 because of Lack of Assurance of Sterility: A recent FDA inspection of Vann Healthcare Services facility revealed deficiencies that raise concerns about the pharmacy\'s ability to consistently assure sterility of their products.
    Vann Healthcare Services Inc, Ongoing Class II recall of Tri-mix #4 (Papaverine 30 mg, Phentolamine 1 mg, Prostaglandin-1 10 mcg/mL), packaged in 10 mL sterile glass vials, Rx, Vann Healthcare Pharmacy, 1220 N Race Street, Glasgow, KY 42141 because of Lack of Assurance of Sterility: A recent FDA inspection of Vann Healthcare Services facility revealed deficiencies that raise concerns about the pharmacy's ability to consistently assure sterility of their products.

    Http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0312-2015&w=12312014&lang=eng
    31 Dec 2014
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Papaverine Hydrochloride

    Access Virtual Booth

    Contact Supplier

    View Presentation

    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search